Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance

References

• Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017 - pubmed [Internet]. [ cited 2021 Aug 9]. Available from: https://pubmed.ncbi.nlm.nih.gov/30496104/
   Google Scholar
• Cox ZL, Lenihan DJ. Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. J Card Fail. 2014 Aug;20(8):611–6.
   Web of Science ®Google Scholar
• Iqbal J, Javaid MM. Br J Hosp Med Lond Engl. 2005 Diuretic resistance and its management. Br J Hosp Med (Lond). 2014 Jul;75(7):C103–107. .
   Google Scholar
• Shchekochikhin D, Al Ammary F, Lindenfeld JA, et al. Role of diuretics and ultrafiltration in congestive heart failure. Pharm Basel Switz. 2013 Jul 4;6(7):851–866.
   Google Scholar
• Mecklai A, Subacius H, Katz S. Diuretic resistance and clinical outcomes in patients hospitalized for worsening heart failure: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: outcome Study with Tolvaptan) trial. J Card Fail. 2013 Aug;1(19):S33–4.
   Google Scholar
• Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. 2015 Dec 4;16(12):29060–29068.
   PubMed Web of Science ®Google Scholar
• Tariq S, Aronow WS. Use of inotropic agents in treatment of systolic heart failure. Int J Mol Sci. 2015 Dec 4;16(12):29060–29068.
   PubMed Web of Science ®Google Scholar
• Kyrzopoulos S, Adamopoulos S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol [Internet]. 2005 Mar [cited 2021 Jul 12];99(3):409–413. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0167527304002785
   Web of Science ®Google Scholar
• Lannemyr L, Ricksten S-E, Rundqvist B, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7(16):e008455. 21.
   PubMed Web of Science ®Google Scholar
• Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014 Mar;16(3):281–288.
   PubMed Web of Science ®Google Scholar
• Cavusoglu Y. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure. Expert Opin Pharmacother [Internet]. 2007 Apr [cited 2021 Jul 12];8(5):665–677. Available from: http://www.tandfonline.com/doi/full/10.1517/14656566.8.5.665
   PubMed Web of Science ®Google Scholar
• Zhang S, Wang Z. Effect of recombinant human brain natriuretic peptide (rhBNP) versus nitroglycerin in patients with heart failure: a systematic review and meta-analysis. Medicine (Baltimore). 2016 Nov;95(44):e4757.
   Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. Circulation. 2017 Aug 8;136(6):e137–61.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Kuwahara K, Nakagawa Y, Nishikimi T. Cutting edge of brain natriuretic peptide (BNP) research ― The diversity of BNP immunoreactivity and its clinical relevance. Circ J Internet]. 2018 Sep 25 [cited 2021 Jul 12];82(10):2455–2461. Available from. [];():. : https://www.jstage.jst.go.jp/article/circj/82/10/82_CJ-18-0824/_article
   PubMed Web of Science ®Google Scholar
• Jia Z, Guo M, Zhang L-Y, et al. Levosimendan and nesiritide as a combination therapy in patients with acute heart failure. Am J Med Sci. 2015 May;349(5):398–405.
   Web of Science ®Google Scholar
• Heart failure group of Chinese society of cardiology of Chinese medical association. Chinese heart failure association of Chinese medical doctor association, editorial board of Chinese journal of cardiology. [Chinese guidelines for the diagnosis and treatment of heart failure 2018]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018 Oct 24;46(10):760–789.
   PubMedGoogle Scholar
• Classes of Heart Failure [Internet]. www.heart.org. [cited 2021 Jul 16]. Available from: https://www.heart.org/en/health-topics/heart-failure/what-is-heart-failure/classes-of-heart-failure
   Google Scholar
• Allen JC. Sample size calculation for two independent groups: a useful rule of thumb. Proc Singap Healthc. 2011 Jun 1;20(2):138–140.
   Google Scholar
• Diuretic Resistance - PubMed [Internet]. [cited 2021 Aug 9]. Available from: https://pubmed.ncbi.nlm.nih.gov/27814935/
   Google Scholar
• Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000 Jul 27;343(4):246–253.
   PubMed Web of Science ®Google Scholar
• He X-M, Chen L, Luo J-B, et al. Effects of rhBNP after PCI on non-invasive hemodynamic in acute myocardial infarction patients with left heart failure. Asian Pac J Trop Med. 2016 Aug;9(8):791–795.
   Web of Science ®Google Scholar
• Xing K, Fu X, Wang Y, et al. Effect of rhBNP on renal function in STEMI-HF patients with mild renal insufficiency undergoing primary PCI. Heart Vessels. 2016 Apr;31(4):490–498.
   Web of Science ®Google Scholar
• Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007 Dec 5;21(6):431–435.
   PubMed Web of Science ®Google Scholar
• Yilmaz MB, Yontar C, Erdem A, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009 Jan;24(1):16–21.
   PubMed Web of Science ®Google Scholar
• Pan H-Y, Zhu J-H, Gu Y, et al. Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with different blood BNP levels. BMC Cardiovasc Disord. 2014 Mar;4(14):31.
   Google Scholar
• Pan H-Y, Zhu J-H, Gu Y, et al. Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with differsent blood BNP levels. BMC Cardiovasc Disord. 2014 Dec;14(1):31.
   Google Scholar
• Bocchi EA, Moura LZ, Issa VS, et al. Effects of the recombinant form of the natural human B-type natriuretic peptide and levosimendan on pulmonary hyperventilation and chemosensivity in heart failure: ventilatory response in heart failure. Cardiovasc Ther. 2013 Apr;31(2):100–107.
   Web of Science ®Google Scholar
• Qiu J, Jia L, Hao Y, et al. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017 Sep;1(184):30–36.
   Google Scholar
• Pang PS, Cleland JGF, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J. 2008 Mar;29(6):816–824.
   PubMed Web of Science ®Google Scholar